Neurocrine Biosciences
NBIX
#1450
Rank
NZ$25.27 B
Marketcap
NZ$253.52
Share price
0.09%
Change (1 day)
4.59%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

Earnings for Neurocrine Biosciences (NBIX)

Earnings in 2025 (TTM): NZ$1.00 Billion

According to Neurocrine Biosciences 's latest financial reports the company's current earnings are NZ$2.68 Billion. In 2024 the company made an earning of NZ$1.05 Billion, an increase over its 2023 earnings that were of NZ$0.53 Billion. The earnings displayed on this page is the company's Pretax Income.

Earnings history for Neurocrine Biosciences from 1996 to 2025

Annual earnings

Year Earnings Change
2025 (TTM) NZ$1.00 B-4.61%
2024 NZ$1.05 B96.41%
2023 NZ$0.53 B41.13%
2022 NZ$0.37 B73.74%
2021 NZ$0.21 B-8.82%
2020 NZ$0.23 B77.78%
2019 NZ$0.13 B49.83%
2018 NZ$89.91 M-142.57%
2017 -NZ$0.22 Billion-14.73%
2016 -NZ$0.25 Billion53.15%
2015 -NZ$0.17 Billion46.25%
2014 -NZ$0.12 Billion29.66%
2013 -NZ$85.29 Million-3530.8%
2012 NZ$2.48 M-95.73%
2011 NZ$58.23 M
2009 -NZ$81.87 Million-45.38%
2008 -NZ$0.15 Billion-58.87%
2007 -NZ$0.37 Billion87.3%
2006 -NZ$0.2 Billion351.97%
2005 -NZ$43.05 Million-52.09%
2004 -NZ$89.85 Million-10.98%
2003 -NZ$0.11 Billion
2001 -NZ$75.34 Million
1999 -NZ$33.98 Million108.32%
1998 -NZ$16.31 Million
1996 NZ$4.97 M

Earnings for similar companies or competitors

Company Earnings Earnings differencediff. Country
Repligen
RGEN
NZ$44.88 M-95.52%๐Ÿ‡บ๐Ÿ‡ธ USA
Royalty Pharma
RPRX
NZ$2.71 B 171.24%๐Ÿ‡ฌ๐Ÿ‡ง UK
Palatin Technologies
PTN
-NZ$8.24 Million-100.82%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$38.63 B 3,758.64%๐Ÿ‡บ๐Ÿ‡ธ USA
AbbVie
ABBV
NZ$2.84 B 184.64%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
NZ$20.34 B 1,932.24%๐Ÿ‡บ๐Ÿ‡ธ USA
ANI Pharmaceuticals
ANIP
NZ$86.78 M-91.33%๐Ÿ‡บ๐Ÿ‡ธ USA
Athersys
ATHX
-NZ$71.7 Million-107.16%๐Ÿ‡บ๐Ÿ‡ธ USA